INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To evaluate the short-term visual acuity and anatomic responses after intravitreal bevacizumab (Avastin, Genentech) treatment in patients with retinal angiomatous proliferation (RAP). METHODS: The authors conducted a retrospective review of consecutive patients with newly diagnosed or recurrent RAP treated with intravitreal bevacizumab (1.25 mg) during a 3-month period. Complete ocular examination was performed at baseline and follow-up visits. Interval data were analyzed statistically at 1 and 3 months follow-up. RESULTS: Twenty-three eyes of 23 patients underwent intravitreal bevacizumab treatment. The mean age of patients was 81.1 years, median baseline visual acuity of treated eyes was 20/80 (range 20/25-20/800), and mean baseline central macular thickness was 335 mum (optical coherence tomography was available for 22 eyes). Nine eyes had retinal pigment epithelial detachments (PEDs) at baseline. At 1-month follow-up, the median acuity improved to 20/60 (range 20/30-20/400) (P < 0.001), mean central macular thickness decreased to 202 microm (P < 0.001), and PED was present in only 2 eyes (P = 0.016). Seven of 23 eyes at 1 month (30.4%) had improved visual acuity, defined as halving of the visual angle, and no eyes had worse acuity, defined as doubling of the visual angle. Of the 17 eyes available for 3-month follow-up, 5 eyes (29.4%) had better visual acuity, 1 eye (5.9%) had worse acuity, and the remaining 11 (64.7%) had the same acuity. The median visual acuity at month 3 was 20/60 (range 20/25-20/400). There were no thromboembolic phenomena, endophthalmitis cases, retinal detachments, or any other adverse events. CONCLUSION: Treatment of RAP with intravitreal bevacizumab during this retrospective review resulted in a significant decrease in macular thickness and improvement or stabilization of visual acuity. Further long-term investigation is warranted given the promising short-term results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
TYPE 3 NEOVASCULARIZATION: The Expanded Spectrum of Retinal Angiomatous Proliferation
FREUND, K. B., -VAN HO, I., BARBAZETTO, I. A., KOIZUMI, H., LAUD, K., FERRARA, D., MATSUMOTO, Y., SORENSON, J. A., & YANNUZZI, L. (2008) · Retina · doi:10.1097/iae.0b013e3181669504 · Cited by 295
Self-citationDorrell, M. I., Aguilar, E., Jacobson, R., Yanes, O., Gariano, R., Heckenlively, J., Banin, E., Ramirez, G. A., Gasmi, M., Bird, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35977 · Cited by 127
“In the Vldlr –/– retina, VEGF upregulation is observed in photoreceptors and RPE and partici-Table (45, 46).”
Resveratrol Inhibits Pathologic Retinal Neovascularization in Vldlr−/−Mice
Hua, J., Guerin, K. I., Chen, J., Michán, S., Stahl, A., Krah, N. M., Seaward, M. R., Dennison, R. J., Juan, A. M., Hatton, C. J., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6496 · Cited by 94
RETINAL ANGIOMATOUS PROLIFERATION: Natural History and Progression of Visual Loss
VIOLA, F., MASSACESI, A., ORZALESI, N., RATIGLIA, R., & STAURENGHI, G. (2009) · Retina · doi:10.1097/iae.0b013e3181a395cb · Cited by 79
Metadata
- Authors
- MEYERLE, C. B., FREUND, K. B., ITURRALDE, D., SPAIDE, R. F., SORENSON, J. A., SLAKTER, J. S., KLANCNIK, J. M., FISHER, Y. L., COONEY, M. J., & YANNUZZI, L. A.
- Venue
- Retina
- Published
- 2007-04
- Volume
- 27
- Issue
- 4
- Pages
- 451-457
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1999946691
- Cited by
- 88
- References
- 0
- FWCI
- 14.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION. https://app.cochat.ai/papers/10.1097/iae.0b013e318030ea80
- The paper
- MEYERLE, C. B., FREUND, K. B., ITURRALDE, D., SPAIDE, R. F., SORENSON, J. A., SLAKTER, J. S., KLANCNIK, J. M., FISHER, Y. L., COONEY, M. J., & YANNUZZI, L. A. (2007). INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION. Retina. https://doi.org/10.1097/iae.0b013e318030ea80
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.